Literature DB >> 28256955

Preconception genetic carrier screening: use and problems.

Viroj Wiwanitkit1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28256955      PMCID: PMC5361435          DOI: 10.1080/03009734.2016.1230158

Source DB:  PubMed          Journal:  Ups J Med Sci        ISSN: 0300-9734            Impact factor:   2.384


× No keyword cloud information.
The recent publications on preconception health and care are very interesting (1). Indeed, the ethical issues are important concerns. The published article by Kihlbom focused upon preconception genetic screening with expanded panels, but it is only for one trait (2). I would like to share the practice in my country on the screening of complex endemic genetic problems. In Thailand, genetic carrier screening for preconception thalassemia and hemoglobin disorders has been used for a long time, and it has become accepted as an important policy for management of these endemic hemoglobin disorders (3). There are no problems as regards acceptance amongst the local people. Key factors might be the campaign for health education concerning the importance and seriousness of the disease and making people aware of the problems of the affected families in the community (4).
  4 in total

1.  Genetic counseling for thalassemia screening in resource limited setting: a case study.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Clin Lab       Date:  2014       Impact factor: 1.138

2.  Community participation for thalassemia prevention initiated by village health volunteers in northeastern Thailand.

Authors:  Yupin Jopang; Suthep Petchmark; Arunee Jetsrisuparb; Kanokwan Sanchaisuriya; Pattara Sanchaisuriya; Frank Peter Schelp
Journal:  Asia Pac J Public Health       Date:  2012-02-13       Impact factor: 1.399

3.  Why is preconception health and care important?

Authors:  Tanja Tydén
Journal:  Ups J Med Sci       Date:  2016-08-03       Impact factor: 2.384

4.  Ethical issues in preconception genetic carrier screening.

Authors:  Ulrik Kihlbom
Journal:  Ups J Med Sci       Date:  2016-07-08       Impact factor: 2.384

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.